International journal of clinical practice · 2009
Vitamin D3 is not effective in the treatment of chronic chilblains.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Souwer I H, Lagro-Janssen A L M
Аннотация
BACKGROUND: Chronic chilblains is a common disease causing major restrictions in daily life, nevertheless little is known about effective treatment. In a literature search, we found thin evidence of three interventions: fluocinolone cream, nifedipine and vitamin D3.
OBJECTIVE: We have conducted a study to assess the effect of oral administration of 2000 IU vitamin D3 per day on patients suffering from chronic chilblains.
METHODS: The study was based on a self-controlled design. The study population consisted of patients with a confirmed diagnosis. Outcome measurement was the change in severity of the complaints and disability. We checked for interference by temperature and other confounders.
LIMITATIONS: The size of the cohort (n = 33) was a limitation.
RESULTS: After correction for confounding factors, 19% of the subjects reported fewer complaints and 6% fewer disability, in both the placebo and vitamin D3 treatment groups.
CONCLUSION: Oral administration of 2000 IU vitamin D3 per day is not better than placebo in the treatment of patients with chronic chilblains.
OBJECTIVE: We have conducted a study to assess the effect of oral administration of 2000 IU vitamin D3 per day on patients suffering from chronic chilblains.
METHODS: The study was based on a self-controlled design. The study population consisted of patients with a confirmed diagnosis. Outcome measurement was the change in severity of the complaints and disability. We checked for interference by temperature and other confounders.
LIMITATIONS: The size of the cohort (n = 33) was a limitation.
RESULTS: After correction for confounding factors, 19% of the subjects reported fewer complaints and 6% fewer disability, in both the placebo and vitamin D3 treatment groups.
CONCLUSION: Oral administration of 2000 IU vitamin D3 per day is not better than placebo in the treatment of patients with chronic chilblains.